Source: Veterinary 33 

Merck Animal Health, also known as MSD Animal Health outside the U.S. and Canada, has finalized its acquisition of Elanco’s aquaculture business. This strategic move significantly bolsters Merck’s presence in the aquaculture industry, integrating a range of advanced products aimed at enhancing fish health and sustainability. The acquisition includes key products like CLYNAV®, a DNA-based vaccine, and IMVIXA®, an anti-parasitic treatment, which are pivotal in managing fish diseases and improving overall fish welfare.

This expansion aligns with Merck’s commitment to addressing the growing global demand for sustainable protein sources and ensuring food safety. By incorporating Elanco’s aqua portfolio, Merck aims to provide comprehensive solutions that support the health and productivity of farmed fish, a critical component of the global food supply. The acquisition underscores Merck’s dedication to innovation in animal health and its proactive approach to meeting the challenges of a burgeoning aquaculture market.

Read the full story HERE: https://www.veterinary33.com/veterinary-today/latest-news/2167/merck-animal-health-completes-acquisition-of-elanco-s-aqua-business.html